Acquisition signals Be aware that Boldscience was acquired by Minds + Assembly in November 2024, which may lead to strategic realignments, new client portfolios, and potential integration needs. This presents an opportunity to engage with the broader combined entity and identify cross-sell channels for medical communications and patient engagement services.

Specialized leadership Kristin Ludwig's appointment as Senior Vice President to lead a new patient advocacy and engagement division signals a push into patient-centric programs. Target conversations around patient education, advocacy initiatives, and disease-area patient engagement to align with the new division’s focus.

Growth potential Revenue bracket of 100 to 250 million indicates a mid-market scale with likely ongoing client diversification. Position Boldscience as a partner capable of handling complex global medical communications programs for pharmaceutical clients seeking scalable, scientifically rigorous storytelling.

Tech-forward The tech stack includes modern web technologies (React, Vite) and integrated tools, suggesting capacity for digital and multichannel campaigns, data-driven content, and efficient delivery. Propose solutions that leverage digital engagement, interactive medical education, and scalable content production.

Industry positioning As a globally oriented medical communications agency with emphasis on bold, creative science communication, Boldscience can differentiate by offering integrated strategies that combine scientific rigor with impactful storytelling for pharmaceutical brands seeking to simplify complex science and improve patient outcomes.